Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is…
10 analysts rate CRBP Buy on consensus.
Consensus price target: $40.56 (+1036.13% upside from $3.57)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Ben Yong director | Sep 14, 2026 | Sale | 2,000 | $15.68K |
| Saxena Nishant C Chief Business Officer | Aug 11, 2026 | Purchase | 2,600 | $25.04K |
| Kung Winston director | Jun 10, 2026 | Sale | 2,026 | $16.03K |
| Jenkins John Kenneth director | Jun 10, 2026 | Sale | 4,800 | $37.99K |
| Altmeyer Anne director | Jun 10, 2026 | Sale | 2,412 | $19.09K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-78.54M |
| 2024 | $0 | — | $-40.21M |
| 2023 | $0 | — | $-44.6M |
Stock data for CRBP: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics